A Bioavailability Study on Dronabinol

NCT03098940 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-04-04

No results posted yet for this study

Summary

This study is a two part study

Conditions

  • THC

Interventions

DRUG

Chewing Gum

During the study healthy subjects will receive single doses of the various strengths of dronabinol

Sponsors & Collaborators

  • Axim Biotechnologies

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2018-04-30
Completion
2018-09-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03098940 on ClinicalTrials.gov